Cargando…

A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer

Bladder cancer (BC) is a frequently diagnosed cancer with high mortality. Male patients have a higher risk of developing BC than female patients. As a type of caspase-independent cell death, necroptosis plays a significant role in the occurrence and progression of BC. The aberrant function of long n...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yuzhou, Li, Jiacheng, Tang, Chenhao, He, Kangwei, Shan, Donggang, Yan, Shenze, Deng, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158872/
https://www.ncbi.nlm.nih.gov/pubmed/37145007
http://dx.doi.org/10.1097/MD.0000000000033664
_version_ 1785037020052062208
author Jin, Yuzhou
Li, Jiacheng
Tang, Chenhao
He, Kangwei
Shan, Donggang
Yan, Shenze
Deng, Gang
author_facet Jin, Yuzhou
Li, Jiacheng
Tang, Chenhao
He, Kangwei
Shan, Donggang
Yan, Shenze
Deng, Gang
author_sort Jin, Yuzhou
collection PubMed
description Bladder cancer (BC) is a frequently diagnosed cancer with high mortality. Male patients have a higher risk of developing BC than female patients. As a type of caspase-independent cell death, necroptosis plays a significant role in the occurrence and progression of BC. The aberrant function of long non-coding RNAs (lncRNAs) plays an indispensable role in GI. However, the relationship between lncRNA and necroptosis in male patients with BC remains unclear. The clinical information and RNA-sequencing profiles of all BC patients were retrieved from The Cancer Genome Atlas Program. A total of 300 male participants were selected for the study. We conducted to identify the necroptosis-related lncRNAs (NRLs) by Pearson correlation analysis. Subsequently, least absolute shrinkage and selection operator Cox regression were conducted to establish a risk signature with overall survival-related NRLs in the training set and to validate it in the testing set. Finally, we verified the effectiveness of the 15-NRLs signature in prognostic prediction and therapy via survival analysis, receiver operating characteristic curve analysis, and Cox regression. Furthermore, we analyzed the correlation between the signature risk score and pathway enrichment analysis, immune cell infiltration, anticancer drug sensitivity, and somatic gene mutations. We developed 15-NRLs (AC009974.1, AC140118.2, LINC00323, LINC02872, PCAT19, AC017104.1, AC134312.5, AC147067.2, AL139351.1, AL355922.1, LINC00844, AC069503.1, AP003721.1, DUBR, LINC02863) signature, and divided patients into a high-risk group and low-risk group through the median risk score. Kaplan–Meier and receiver operating characteristic curves showed that the prognosis prediction had satisfactory accuracy. Cox regression analysis indicated that the 15-NRLs signature was a risk factor independent of various clinical parameters. Additionally, immune cell infiltration, half-maximal inhibitory concentration, and somatic gene mutations differed significantly among different risk subsets, implying that the signature could assess the clinical efficacy of chemotherapy and immunotherapy. This 15-NRLs risk signature may be helpful in assessing the prognosis and molecular features of male patients with BC and improve treatment modalities, thus can be further applied clinically.
format Online
Article
Text
id pubmed-10158872
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101588722023-05-05 A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer Jin, Yuzhou Li, Jiacheng Tang, Chenhao He, Kangwei Shan, Donggang Yan, Shenze Deng, Gang Medicine (Baltimore) 7300 Bladder cancer (BC) is a frequently diagnosed cancer with high mortality. Male patients have a higher risk of developing BC than female patients. As a type of caspase-independent cell death, necroptosis plays a significant role in the occurrence and progression of BC. The aberrant function of long non-coding RNAs (lncRNAs) plays an indispensable role in GI. However, the relationship between lncRNA and necroptosis in male patients with BC remains unclear. The clinical information and RNA-sequencing profiles of all BC patients were retrieved from The Cancer Genome Atlas Program. A total of 300 male participants were selected for the study. We conducted to identify the necroptosis-related lncRNAs (NRLs) by Pearson correlation analysis. Subsequently, least absolute shrinkage and selection operator Cox regression were conducted to establish a risk signature with overall survival-related NRLs in the training set and to validate it in the testing set. Finally, we verified the effectiveness of the 15-NRLs signature in prognostic prediction and therapy via survival analysis, receiver operating characteristic curve analysis, and Cox regression. Furthermore, we analyzed the correlation between the signature risk score and pathway enrichment analysis, immune cell infiltration, anticancer drug sensitivity, and somatic gene mutations. We developed 15-NRLs (AC009974.1, AC140118.2, LINC00323, LINC02872, PCAT19, AC017104.1, AC134312.5, AC147067.2, AL139351.1, AL355922.1, LINC00844, AC069503.1, AP003721.1, DUBR, LINC02863) signature, and divided patients into a high-risk group and low-risk group through the median risk score. Kaplan–Meier and receiver operating characteristic curves showed that the prognosis prediction had satisfactory accuracy. Cox regression analysis indicated that the 15-NRLs signature was a risk factor independent of various clinical parameters. Additionally, immune cell infiltration, half-maximal inhibitory concentration, and somatic gene mutations differed significantly among different risk subsets, implying that the signature could assess the clinical efficacy of chemotherapy and immunotherapy. This 15-NRLs risk signature may be helpful in assessing the prognosis and molecular features of male patients with BC and improve treatment modalities, thus can be further applied clinically. Lippincott Williams & Wilkins 2023-05-05 /pmc/articles/PMC10158872/ /pubmed/37145007 http://dx.doi.org/10.1097/MD.0000000000033664 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 7300
Jin, Yuzhou
Li, Jiacheng
Tang, Chenhao
He, Kangwei
Shan, Donggang
Yan, Shenze
Deng, Gang
A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer
title A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer
title_full A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer
title_fullStr A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer
title_full_unstemmed A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer
title_short A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer
title_sort risk signature of necroptosis-related lncrna to predict prognosis and probe molecular characteristics for male with bladder cancer
topic 7300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158872/
https://www.ncbi.nlm.nih.gov/pubmed/37145007
http://dx.doi.org/10.1097/MD.0000000000033664
work_keys_str_mv AT jinyuzhou arisksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT lijiacheng arisksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT tangchenhao arisksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT hekangwei arisksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT shandonggang arisksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT yanshenze arisksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT denggang arisksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT jinyuzhou risksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT lijiacheng risksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT tangchenhao risksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT hekangwei risksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT shandonggang risksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT yanshenze risksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer
AT denggang risksignatureofnecroptosisrelatedlncrnatopredictprognosisandprobemolecularcharacteristicsformalewithbladdercancer